Remove Food and Drug Administration Remove Government Remove Prospecting Remove Safety
article thumbnail

Primate models in pharma: What the future holds

Pharmaceutical Technology

However, according to the US Food and Drug Administration (FDA), non-human primates are still the most scientifically relevant large model to test biologic drugs for safety. This is to ensure patient safety, as outlined in The Medicines for Human Use (Clinical Trials) Regulations 2004.

Pharma 98
article thumbnail

SNIPR targets antibiotic resistance with CRISPR-based gene therapy trial

Pharmaceutical Technology

The Danish CRISPR biotech SNIPR BIOME has released the first glimpse at the safety profile for SNIPR001, a gene therapy intended to target antibiotic resistance. Interim clinical results from a Phase I trial have demonstrated SNIPR001’s safety in healthy volunteers. SNIPR001 consists of four CRISPR-edited phages targeting E.Coli.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Malaria vaccines must beat logistics issues for efficient access

Pharmaceutical Technology

Storage in other conditions can cause damage to the antigen or adjuvant and reduce the vaccine’s safety or efficacy. Long-term storage and delivery of vaccines are vital, especially as governments seek to vaccinate rural and remote communities. The majority of this rise came from the African region.

article thumbnail

Q&A: As RSV vaccine approvals loom, regulators need to devise vaccination strategies

Pharmaceutical Technology

After a US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) Advisory Committee (AdCom) meeting in March 2023 voted unanimously in support of GSK’s respiratory syncytial virus vaccine, the odds for an approval have increased.